NEWS

 

Title Date
The Board of Directors resolved not to distribute dividends. 2021-02-26
Oneness announces a resolution by the Board of Directors on 2020 consolidated financial statements of the Company. 2021-02-26
Oneness announces a resolution by the Board of Directors on donating to the Medical Excellence TAIWAN. 2021-02-26
Oneness Board of Directors resolved to convene the Annual Shareholders' Meeting of 2021. 2021-02-26
Oneness's trading securities have met the "Attention Securities' criteria" for announcement 2021-02-26
Oneness announces on behalf of Cotton Field Organic Farm Inc., a major subsidiary, for a resolution by BODs on convening the 2021 Annual Shareholders' Meeting 2021-02-24
Oneness received the letter from MOHW informing that ON101 for DFUs has obtained the new drug approval and its drug certificate will be notified for receipt. 2021-02-24
Oneness submits an IND to US FDA on a phase II clinical trial on severe asthma of FB704A, a mAb developed from its own platform. 2021-02-15
Oneness will not proceed with the ON101 Phase3 clinical trial (ON101CLCT04) application with BfArM of Germany based on strategic consideration. 2021-02-09
Oneness Biotech Co.,LTD receives a U.S. patent titled "TOPICAL FORMULATION FOR PROMOTING WOUND HEALING" on the developing new drug: ON101 Cream. 2021-02-02
Oneness Biotech Co.,LTD receives a European patent on antagonistic PDL1 aptamers. 2021-01-29
Oneness Biotech Co.,LTD receives a European patent on antagonistic CTLA-4 aptamers. 2021-01-29
Oneness announces that LEO PHARMA made the 2nd upfront payment of US$15.12MM according to the agreement. A total of US$33.6MM upfront payments have been received. 2021-01-14
Oneness Biotech to Present at the 39th Annual J.P. Morgan Healthcare Conference 2021-01-04